Charles River Laboratories International (NYSE:CRL) CAO Sells $1,730,225.10 in Stock

Charles River Laboratories International, Inc. (NYSE:CRL) CAO Michael Gunnar Knell sold 6,645 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $260.38, for a total transaction of $1,730,225.10. Following the transaction, the chief accounting officer owned 11,852 shares in the company, valued at $3,086,023.76. This trade represents a 35.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $284.99 on Thursday. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. The firm has a market capitalization of $13.61 billion, a PE ratio of -58.76, a price-to-earnings-growth ratio of 2.92 and a beta of 1.38. Charles River Laboratories International, Inc. has a 12-month low of $144.26 and a 12-month high of $288.02. The firm has a 50-day moving average price of $220.98 and a 200-day moving average price of $190.27.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.25. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period last year, the company earned $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, equities research analysts forecast that Charles River Laboratories International, Inc. will post 11.35 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on CRL shares. Royal Bank Of Canada raised their price target on shares of Charles River Laboratories International from $215.00 to $282.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Robert W. Baird set a $291.00 price objective on Charles River Laboratories International in a research note on Thursday, August 6th. TD Cowen lifted their price objective on shares of Charles River Laboratories International from $235.00 to $300.00 and gave the company a “buy” rating in a research note on Monday. Barclays reaffirmed an “overweight” rating and set a $300.00 target price on shares of Charles River Laboratories International in a report on Wednesday, August 5th. Finally, Piper Sandler set a $300.00 price objective on shares of Charles River Laboratories International in a report on Monday. Twelve equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $255.65.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in Charles River Laboratories International by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock valued at $1,174,374,000 after purchasing an additional 47,432 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Charles River Laboratories International by 115.8% during the 4th quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after buying an additional 1,446,972 shares during the last quarter. State Street Corp raised its position in shares of Charles River Laboratories International by 2.2% during the 4th quarter. State Street Corp now owns 1,871,688 shares of the medical research company’s stock valued at $373,364,000 after buying an additional 40,535 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Charles River Laboratories International by 14.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock valued at $285,001,000 after buying an additional 210,260 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Charles River Laboratories International by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 1,276,502 shares of the medical research company’s stock valued at $254,186,000 after acquiring an additional 9,756 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Key Headlines Impacting Charles River Laboratories International

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Earnings exceeded expectations. Charles River reported fiscal second-quarter adjusted earnings of $3.02 per share, above the $2.77 analyst consensus, while revenue of approximately $1.0 billion also topped expectations of $980.5 million. Management maintained fiscal 2026 earnings guidance of $11.15 to $11.45 per share. Charles River Laboratories Q2 2026 Earnings Call Transcript
• Positive Sentiment: Analyst sentiment remains supportive. Piper Sandler and Barclays set or maintained $300 price targets, while RBC raised its target to $282 and reiterated an outperform rating. JPMorgan also upgraded CRL to overweight with a $310 target. The overall analyst consensus is “Moderate Buy,” with 12 Buy ratings, three Holds and one Sell. Charles River Laboratories Consensus Rating
• Positive Sentiment: Investor focus remains on management’s outlook. Articles reviewing the second-quarter earnings call highlighted analyst questions about Charles River’s operating trends and forward expectations. The discussion helps investors assess whether the earnings beat and 2026 guidance can be sustained. Analyst Questions From Charles River’s Q2 Earnings Call
• Positive Sentiment: Technical momentum is strong. CRL reached a new 52-week high near $277, with trading volume above its average. Shares remain substantially above their 50-day and 200-day moving averages, reinforcing bullish momentum. Charles River Laboratories Sets New 52-Week High
• Negative Sentiment: Multiple insiders sold shares. Director James C. Foster sold 28,733 shares for approximately $7.9 million under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 47.6%. EVP Victoria Creamer separately sold 4,179 shares worth about $1.1 million. The planned transactions may weigh on sentiment, although they do not necessarily indicate weakening business prospects. SEC Insider Transaction Filing

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.